Literature DB >> 17264974

Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?

Samuel K Shinjo1, Otacílio O Maia, Vivian A P Tizziani, Celso Morita, Jussara A L Kochen, Walter Y Takahashi, Ieda M M Laurindo.   

Abstract

Chloroquine diphosphate has been used in the treatment of various rheumatic diseases, including rheumatoid arthritis. The most important of its side effects is retinopathy. If not diagnosed early, this lesion can evolve into irreversible bull's eye maculopathy and visual loss. The aim of this study was to define the outcome of chloroquine-induced maculopathy after cessation of chloroquine therapy and also to identify the risk factors involved in case of retinopathy evolution. The design of this cohort study was longitudinal and retrospective. Over the period spanning 2000 to 2005, out of 607 medical records of patients with rheumatoid arthritis followed in our Division of Rheumatology, 27 had been diagnosed with chloroquine-induced maculopathy through clinical funduscopy with pupil dilation. In all cases, there was immediate chloroquine intake cessation. After a mean time of 5 years, 16 of these patients were available for follow-up and underwent a new ophthalmologic evaluation by funduscopy, using biomicroscopy and angiofluorescein when necessary. Sequelae maculopathy were reconfirmed in all 16 cases, but progression to advanced stage (bull's eye maculopathy) was found in half of the cohort, even though chloroquine had been suspended. All patients complained of visual alterations, but without progression. Comparison between patient groups with and without bull's eye maculopathy revealed a statistically significant longer rheumatoid arthritis disease history in the former group. Also, the bull's eye group had higher dose intakes of chloroquine and over a longer period compared to the other group, but not statistically significant. This study corroborates the progression of maculopathy even after cessation of chloroquine intake, pointing out the need for careful screening in the high-risk patients. Furthermore, it indicates that duration of rheumatoid arthritis disease could be a possible factor linked to worse prognosis of chloroquine-induced maculopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264974     DOI: 10.1007/s10067-006-0478-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  36 in total

1.  Unusual ocular lesions in a case of systemic lupus erythematosus.

Authors:  A CAMBIAGGI
Journal:  AMA Arch Ophthalmol       Date:  1957-03

2.  The field topography of ERG components in man--I. The photopic luminance response.

Authors:  E E Sutter; D Tran
Journal:  Vision Res       Date:  1992-03       Impact factor: 1.886

3.  Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy. A study of 741 patients treated with and without chloroquine drugs.

Authors:  A L SCHERBEL; A H MACKENZIE; J E NOUSEK; M ATDJIAN
Journal:  N Engl J Med       Date:  1965-08-12       Impact factor: 91.245

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  [Ocular toxicity caused by chloroquine: case report].

Authors:  Eliane Terumi Inada; Karina Paula Watanabe; Sérgio Gustavo Tanaka; Luís Antônio Sakakisbara
Journal:  Arq Bras Oftalmol       Date:  2005-07-26       Impact factor: 0.872

6.  Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine.

Authors:  Philip J Penrose; Radouil T Tzekov; Erich E Sutter; Arthur D Fu; Arthur W Allen; Wayne E Fung; Karen W Oxford
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

7.  Long-term course of antimalarial maculopathy after cessation of treatment.

Authors:  M Easterbrook
Journal:  Can J Ophthalmol       Date:  1992-08       Impact factor: 1.882

8.  Ocular toxicity of antimalarials in dermatology: a survey of current practice.

Authors:  N H Cox; W D Paterson
Journal:  Br J Dermatol       Date:  1994-12       Impact factor: 9.302

9.  Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy.

Authors:  H N Bernstein
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

10.  Hydroxychloroquine. Seven-year experience.

Authors:  D R Tobin; G Krohel; R I Rynes
Journal:  Arch Ophthalmol       Date:  1982-01
View more
  10 in total

Review 1.  Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations.

Authors:  Sonia Guha; Erin E Coffey; Wennan Lu; Jason C Lim; Jonathan M Beckel; Alan M Laties; Kathleen Boesze-Battaglia; Claire H Mitchell
Journal:  Exp Eye Res       Date:  2014-09       Impact factor: 3.467

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine.

Authors:  Javad Heravian; Massoud Saghafi; Naser Shoeibi; Samira Hassanzadeh; Mohammad Taghi Shakeri; Maria Sharepoor
Journal:  Int Ophthalmol       Date:  2011-07-12       Impact factor: 2.031

4.  Delayed progression of bull's eye maculopathy.

Authors:  Sunila Jain; Neel Gautam Jain
Journal:  BMJ Case Rep       Date:  2017-06-08

Review 5.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

6.  Chloroquine retinopathy: lipofuscin- and melanin-related fundus autofluorescence, optical coherence tomography and multifocal electroretinography.

Authors:  Ulrich Kellner; Simone Kellner; Silke Weinitz
Journal:  Doc Ophthalmol       Date:  2007-12-16       Impact factor: 2.379

7.  Evaluation of Maculopathy in Patients Using Hydroxychloroquine

Authors:  Adem Uğurlu; Maisa Aslanova; Zafer Cebeci; Nur Kır Mercül
Journal:  Turk J Ophthalmol       Date:  2019-06-27

8.  Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients.

Authors:  Riham S H M Allam; Mai N Abd-Elmohsen; Mohamed M Khafagy; Karim A Raafat; Sherif M Sheta
Journal:  J Ophthalmol       Date:  2015-08-02       Impact factor: 1.909

9.  Lutein Attenuates Both Apoptosis and Autophagy upon Cobalt (II) Chloride-Induced Hypoxia in Rat Műller Cells.

Authors:  Frederic K C Fung; Betty Y K Law; Amy C Y Lo
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 10.  Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis.

Authors:  Yen-Ju Lin; Martina Anzaghe; Stefan Schülke
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.